Search clinical trials for: CD22 CAR-T， B-ALL

Total 157 results

Ruijin Hospital
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

Lymphoma

China
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
The Leeds Teaching Hospitals NHS Trust

Recruiting

Would Artificial Intelligence Reduce Delays to Nurse Response Times (WAiRD)

Nurse's Role

United Kingdom
Xinqiao Hospital of Chongqing
Xuzhou Medical University

Unknown

Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients (MendCART)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III/IV Adult Diffuse Large Cell Lymphoma | Stage III/IV Follicular Lymphoma | Stage III/IV Mantle Cell Lymphoma

China
University of Pennsylvania
Children's Hospital of Philadelphia

Recruiting

CD22 Redirected Autologous T Cells for ALL

B Cell Lymphomas | B Cell Leukemias

United States
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Terminated

CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)

Refractory and Relapsed B Cell Acute Leukemia

China
Juventas Cell Therapy Ltd.

Not yet recruiting

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; 920th Hospital of Joint Logistics Support... and other collaborators

Not yet recruiting

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Istituto Scientifico Romagnolo per lo Studio e...

Unknown

ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate (INO-CD22)

Acute Lymphoblastic Leukemia

Italy
Cristiana Sessa

Completed

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma (IOSI-LND-001)

B-cell Lymphoma Refractory

Switzerland
Shanghai General Hospital, Shanghai Jiao Tong University...

Completed

Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL

Acute Lymphoblastic Leukemia | MRD-positive

China
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (BAH241)

Lymphoma, Follicular | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, in Relapse | MCL | Central Nervous System Lymphoma | Acute Lymphoblastic Leukemia, Adult B-Cell | Non-Hodgkin Lymphoma, B-cell

China
Nantes University Hospital
Gilead Sciences; Institut Cancerologie de l'Ouest

Withdrawn

Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia (EPRALLO)

Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Beijing GoBroad Hospital

Recruiting

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
Beijing GoBroad Hospital

Not yet recruiting

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia
Rong Tao
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia With Failed Remission

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Progressive Disease | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Minimal Residual Disease | Recurrent Chronic Lymphocytic Leukemia | CD19 Positive | CD22...

United States
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Acute Lymphoblastic Leukemia
Beijing Boren Hospital

Recruiting

Study of Anti-CD22 CAR-T Cells Treating Leukemia Children

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

CAR-T for R/R B-NHL

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | CAR - T CD19/CD20/CD22/CD30

China
Zhujiang Hospital
Nanfang Hospital, Southern Medical University

Recruiting

Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL

Therapy Related Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Adult B Acute Lymphoblastic Leukemia

China
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma

United States
Dr. Melody Smith, MD, MS
Orca Biosystems, Inc.

Recruiting

Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)

Lymphoid Leukemia

United States
University College, London

Active, not recruiting

CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies

Burkitt Lymphoma | Acute Lymphoblastic Leukemia

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

B-cell Non-Hodgkin's Lymphoma
Stephan Grupp MD PhD
University of Pennsylvania

Recruiting

Co-administration of CART22-65s and huCART19 for B-ALL

B-cell Acute Lymphoblastic Leukemia | B Lineage Lymphoblastic Lymphoma

United States
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co., Ltd.

Unknown

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma | B-precursor ALL

United States
St. Jude Children's Research Hospital
Pfizer

Recruiting

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States
Nantes University Hospital

Unknown

Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ (RIT 90YEpra)

Acute Lymphoblastic Leukemia

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | CD22 Positive

United States
Gilead Sciences

Withdrawn

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Diffuse Large B-cell Lymphoma | NHL | Non Hodgkin's Lymphoma | Aggressive NHL

United States
KK Women's and Children's Hospital
National University Hospital, Singapore; Singapore General Hospital

Recruiting

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR

Singapore
Stanford University

Active, not recruiting

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Lymphoma | B Cell Lymphoma | Acute Lymphoblastic Leukemia, Pediatric

United States
The Second Affiliated Hospital of Henan University...
First Affiliated Hospital of Wenzhou Medical University; Second Affiliated... and other collaborators

Unknown

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

CD19-positive ALL

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

CAR-T Cell | Ph Positive ALL | Dasatinib

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Refractory Indolent Adult Non-Hodgkin Lymphoma

China
National Institute of Arthritis and Musculoskeletal...

Completed

Humanized LL2IGG to Treat Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

Leukemia

United States
Gilead Sciences

Terminated

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Federal Research Institute of Pediatric Hematology...

Active, not recruiting

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

B-ALL

Russian Federation
Stanford University

Recruiting

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Leukemia | Acute Lymphoblastic Leukemia

United States
Cellectis S.A.

Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

B-cell Acute Lymphoblastic Leukemia

United States, France
Qiu Lugui
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
The First Affiliated Hospital of Soochow University

Enrolling by invitation

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

China
Versailles Hospital

Active, not recruiting

Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL (EWALL-INO)

Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)

France
Institute of Hematology & Blood Diseases Hospital...
Nanjing Legend Biotech Co.

Active, not recruiting

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia

China

Search clinical trials for: CD22 CAR-T， B-ALL

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations